title: Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity.
abstract: Renal failure, mainly due to calcineurin inhibitor (CNI) nephrotoxicity, is the most common complication following orthotopic liver transplantation (ltx). The aim of this study was to evaluate the incidence and course of renal failure in adult ltx patients. Severe acute renal failure in early postoperative period due to impaired hemodynamics and CNI nephrotoxicity, occurred in 14 patients, 3 of whom required dialysis. The creatinine clearance after ltx showed a tendency to decrease, but there was no statistically significant difference (P >.05) in the change in serum creatinine clearance levels between patients treated with tacrolimus (TAC) versus Cyclosporine (CsA) during the first 2 years of follow-up. Fourteen patients required conversion of their regimen because of CNI nephrotoxicity namely, dose reduction (n = 7) or discontinuation of CNI therapy with the replacement by mycophenolate mofetil (MMF) (n = 5) or SRL (n = 5). Dose reduction or CNI withdrawal significantly improved the creatinine clearance (P <.05) without affecting lives graft function. No episode of acute rejection was observed after conversion. Neither conversion of CsA to TAC nor the reverse maneuver significantly influenced the serum creatinine level (P >.05). Reduction of the CNI dose or CNI discontinuation or replacement with MMF or SRL in patients with stable liver but impaired renal function is safe, resulting in a significant improvement in renal function.
authors.affiliation: Department of Immunology, Transplant Medicine and Internal Diseases, Transplantation Institute, Warsaw, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Ziolkowski
authors.forename: L
authors.initials: L
authors.lastname: Paczek
authors.forename: G
authors.initials: G
authors.lastname: Senatorski
authors.forename: M
authors.initials: M
authors.lastname: Niewczas
authors.forename: U
authors.initials: U
authors.lastname: Oldakowska-Jedynak
authors.forename: J
authors.initials: J
authors.lastname: Wyzgal
authors.forename: J
authors.initials: J
authors.lastname: Sanko-Resmer
authors.forename: T
authors.initials: T
authors.lastname: Pilecki
authors.forename: K
authors.initials: K
authors.lastname: Zieniewicz
authors.forename: P
authors.initials: P
authors.lastname: Nyckowski
authors.forename: W
authors.initials: W
authors.lastname: Patkowski
authors.forename: M
authors.initials: M
authors.lastname: Krawczyk
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced*; D000293:Adolescent; D000328:Adult; D065095:Calcineurin Inhibitors; D016572:Cyclosporine / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007668:Kidney / Q000187:drug effects / Q000473:pathology*; D007677:Kidney Function Tests; D016031:Liver Transplantation / Q000276:immunology / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D011184:Postoperative Period; D012189:Retrospective Studies; D016559:Tacrolimus / Q000009:adverse effects*; D013997:Time Factors
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus